China approved 48 first-in-class innovative drugs, as well as a significant number of medications for pediatric and rare diseases, thanks to measures aimed at enhancing review efficiency and ...

With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...

Spectral AI, Inc. (Nasdaq: MDAI) ("Spectral AI” or the "Company”), an artificial intelligence ("AI”) company focused on ...

OS Therapies ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its OST-HER2 listeria ...

Welcome to Plus Therapeutics fourth quarter and full-year 2024 results conference call. Before we begin, we want to advise you that over the course of the call, including any question-and-answer ...

Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of SYMVESS™ in the vascular trauma indication, the development of the product candidates ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in ...

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating resp ...

for use in patients with glioblastoma, leptomeningeal cancer, and soon in children with pediatric brain cancer. Finally, we recently received approval by the US FDA on our application for orphan ...